1. Pink Sheet
  2. >>Market Access

Brazil Consults On How To Price Advanced Therapies

 
• By Francesca Bruce

Brazil’s drug regulator ANVISA has also published its first post-marketing authorization monitoring reports on advanced therapies Yescarta, Zolgenma, Kymriah, Carvykti and Luxturna.

Brazilian money
Brazil wants to establish pricing rules for advanced therapies. (Shutterstock)
Key Takeaways
  • Brazilian authorities are seeking views on how advanced therapies should be priced as a first step towards developing new pricing regulations for these products.
  • Brazilian pricing regulations currently have no provisions for advanced therapies.
  • The medicines regulator, ANVISA, has published post-authorization monitoring reports on several advanced therapies.

The committee that regulates medicine pricing in Brazil, CMED, is seeking feedback from the public on its plan to create specific pricing regulations for advanced therapy medicinal products (ATMPs)

“Pricing advanced therapies involves specific challenges and directly impacts the viability of these treatments,” ANVISA said in a statement

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By Tim Casey

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.

Will International Prices Influence Medicare Price Negotiation?

 
• By Cathy Kelly

A former CMS official suggested the most likely way it could happen is through a Center for Medicare and Medicaid Innovation demonstration.

Managed Access Agreement Fails To Help BioMarin’s Brineura Secure Routine Reimbursement In England

 
• By Francesca Bruce

BioMarin’s ultra-rare disease drug Brineura has breached cost-effectiveness thresholds for highly specialized treatments in England and looks set to be denied routine funding on the National Health Service.

Industry Leaders Grapple With Trump’s Most Favored Nation Pricing Plan

 
• By Jessica Merrill

At the Bank of America health care conference, pharma leaders speculated on the impact of Trump’s most favored nation pricing executive order on US and European markets.

More from Advanced Technologies